Tuesday, 28 Jan 2020

You are here

Bimekizumab Add-on Therapy in Rheumatoid Arthritis

Bimekizumab is a dual inhibitor of IL-17A and IL-17F that has been shown to be effective in psoriasis and psoriatic arthritis. A proof-of-concept study shows that giving bimekizumab to rheumatoid arthritis (RA) patients not adequately controlled by certolizumab pegol (CZP) resulted in a rapid decrease in disease activity achieved after 12 weeks of treatment. These findings are novel as anti-IL-17 monoclonal antibody therapy has previously been shown to be ineffective in RA. 

This phase 2a, double-blind, proof-of-concept study enrolled 159 patients with moderate-to-severe RA who had active disease after 8 weeks of open-label CZP treatment.  There were 79 incomplete responders who continued their CZP but were randomized to either placebo or bimekizumab (240 mg loading dose then 120 mg Q2W). The primary endpoints was the change in DAS28(CRP) at week 20. 

By week 20, there was a greater reduction in DAS28(CRP) in the CZP-IR plus bimekizumab group compared with the CZP-IR plus placebo group (61% vs 48%). The decrease in DAS28(CRP) was -1.41 for the BIM+CZP group vs. -0.82 for the CZP+PBO group. 

There were more overall infections (TEAEs) with CZP plus bimekizumab (50.0%) compared to CZP plus placebo (22.2%). There was only one serious infection in each group by study end. 

These results suggest the possible utility of a dual IL-17 inhibitor, bimekizumab, in RA patients not responding to TNF inhibition. 

The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

Which insurance carrier will agree to pay for the COST of certolizumab pegol (CZP) PLUS bimekizumab ? Why not use MTX before using bimekizumab ? or use low dose steroids? Dr. NAC

More Like This

2019 EULAR Recommendations for the Management of Rheumatoid Arthritis

The 2019 update to the EULAR recommendations on the use of synthetic and biological disease-modifying antirheumatic drugs in rheumatoid arthritis (RA) have been published in Annals of Rheumatic Disease - highlighting the efforts of an international consensus committee effort. In the end, the task force put forth 5 overarching principles and 12 recommendations concerning use of conventional synthetic DMARDs, glucocorticoids, biological DMARDs, biosimilar DMARDs, and targeted synthetic DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib).

Low Risk of Inflammatory Arthritis in Hidradenitis Suppurativa Patients

JAMA Dermatology reports that after the onset and diagnosis of hidradenitis suppurativa (HS), such patients have a higher risk of certain forms inflammatory arthritis.

Best of 2019 - War on RA - Part 1: Walk on the Moon

It’s a great time to be a rheumatologist and to manage RA. But, if you keep doing what you’re doing, you’re going to keep getting what you’ve got.

Best of 2019 - War on RA - Part 3: Useless Drugs

We have options that are endless – we have 28 biologics in rheumatology; 19 approved for RA in the last 20 years, but 15 of these are me-too copies or biosimilars. We currently have 2 JAK inhibitors and may have 3 or 4 by year end. But what we really need is the right drug, at the right time, in the right patient – but how will we know.

Link Between Obstructive Lung Disease and Developing RA?

We all know that the microbiome in the gut may be very important for multiple immune diseases. However, new findings from the ACR, 2019 in Atlanta reinforce how important the interface is between the lungs and developing rheumatoid arthritis.